Spinraza in the UK ‒ questions and answers – TreatSMA
Biogen to study higher dose of Spinraza in SMA patients
From Idea to Injection: How Spinraza Came to Be - SMA News Today
Official HCP Homepage | SPINRAZA® (nusinersen) | HCP
HSE approves Spinraza after lengthy campaign by patients
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
Progress on Early Access Programme of Spinraza – TreatSMA
Spinraza - NPS MedicineWise
Biogen's blockbuster rare disease drug could be in trouble
Biogen announces new data providing further evidence for SPINRAZA (nusinersen) as a treatment for SMA - Spinal News International
Novartis' £1.79M gene therapy Zolgensma scores cost watchdog's backing, threatening Biogen's Spinraza | FiercePharma
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
Biogen bounces back with Spinraza early treatment data - PMLiVE
Hydrocephalus a side effect of Spinraza? - SMA News Today Forums
NHS to use world's most expensive drug to treat spinal muscular atrophy | NHS | The Guardian
NHS labels Spinraza deal “one of the most comprehensive in the world”
Safety | SPINRAZA® (nusinersen) HCP
Spinraza - FDA prescribing information, side effects and uses
Biogen update on European access to Spinraza – TreatSMA
NHS to use world's most expensive drug to treat spinal muscular atrophy | NHS | The Guardian
Biogen provides information on upcoming Spinraza EU label | SMA Europe
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
